

**INTERNATIONAL CANCER IMAGING SOCIETY**

**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED**

**28TH FEBRUARY 2023**

**Charity number 1082082**  
**Company number 03908709**

**INTERNATIONAL CANCER IMAGING SOCIETY**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED**  
**28TH FEBRUARY 2023**

<b>Contents</b>	<b>Page</b>
Report of the Trustees	1-10
Independent Examiner's Report	11
Statement of Financial Activities	12
Balance Sheet	13
Notes to the Accounts	14-17

# INTERNATIONAL CANCER IMAGING SOCIETY

## REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2023

---

The trustees (who are also the directors of the company) present their report and the independently examined financial statements of the charitable company for the year ended 28th February 2023.

The Board of Trustees is satisfied with the performance of the charity during the year, considers that the charity is able to continue its activities during the coming year and that the charity's assets are adequate to fulfil its obligations.

The trustees who served during the year and to the date of this report were:

Prof. Dame Janet Husband  
Prof. Rodney Reznick  
Dr. Conor Collins (resigned 26 October 2022)  
Prof. Stefan Diederich  
Prof. Anwar Padhani  
Prof. Harriet Thoeny  
Prof. Dow-Mu Koh  
Prof. Andrea Rockall  
Dr. Beth McCarville  
Dr. Evis Sala  
Prof. Willem Oyen  
Dr. Rosemarie Forstner  
Dr. Giovanni Morana  
Dr. Aslam Sohaib  
Prof. Rodney Hicks  
Prof. Annick Van Den Abbeele  
Prof. Olivier Lucidarme  
Dr. Thierry Huisman  
Prof. Pek Lan Khong  
Prof. Giuseppe Petralia

The key management personnel are the trustees and Maureen Watts - General Manager.

**Secretary and Registered Office** Mr Trevor Pereira  
41 Waddington Way  
London  
SE19 3UB

**Bankers** Barclays Bank plc  
9 Portman Square  
London  
W1A 3AL

**Independent  
Examiners** Jacob Cavenagh & Skeet  
5 Robin Hood Lane  
Sutton  
Surrey  
SM1 2SW

**Solicitors** Radcliffes Le Brasseur  
5 Great College Street  
Westminster  
London  
SW1P 3SJ



## **INTERNATIONAL CANCER IMAGING SOCIETY**

### **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)**

---

#### **Objects and Activities to achieve a public benefit**

The Society was incorporated on 18th January 2000 to advance education and research within the field of oncological imaging and human tumour behaviour worldwide including in particular:

- a) The integration of cross sectional imaging techniques, including computed tomography, magnetic resonance imaging, ultrasonography and nuclear medicine techniques, conventional radiology and developing new imaging modalities
- b) The study and analysis of the efficacy and outcome of diagnostic imaging studies
- c) The promotion of interest in oncology and the facilitation of exchange of ideas by the organisation of scientific meetings, multicentre research studies, seminars and conferences on oncological imaging
- d) The provision of postgraduate courses in oncological imaging

The main activities undertaken by the Society to meet these objects are through like-minded engagement with oncologic societies and imaging teaching courses held through the year.

The Society has as its charitable purpose the advancement of health or saving lives, promoting as it does the sharing of information and latest developments within oncological imaging and tumour behaviour worldwide. The resulting benefit to the public is that attendees at teaching courses are able to put into practice the latest research, technologic developments and findings to improve the treatment and care given to cancer patients.

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and in planning future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

#### **Achievements and Performance**

With the ongoing repercussions of the pandemic, educational activity continued to be conducted online for the first six months of this period. The series of bi-monthly webinars, first established in 2020, continued successfully by attracting significant interest and worldwide engagement with the Society. The webinars are free to watch live and subsequently available in the ICIS members' area of the website. A range of topics is covered, often providing the opportunity to promote forthcoming ICIS Interactive workshops or other Society activities.

Plans to conduct the postponed AI & Machine Learning meeting in Lisbon, Portugal, in May 2022 were reviewed and following due consideration, the decision was taken to postpone again with a view to holding the course in summer 2023.

The preference for delivering ICIS Interactive Masterclass workshops online remained in place with the gynaecological cancers course conducted in June 2022, selling out all 24 available places. On this occasion a new online radiology platform, Collective Minds Radiology (CMRAD), was utilised to deliver the workshop, with favourable feedback from both faculty and delegates. Individual access to the platform is enabled, allowing independent review of the workshop cases by each attendee. This success has translated into a longer-term relationship with CMRAD; a one-year contract was signed in February 2022, engaging their services throughout the coming year to conduct future ICISi masterclasses or other educational activities which can be adapted for delivery through the CMRAD platform.



## INTERNATIONAL CANCER IMAGING SOCIETY

### REPORT OF THE TRUSTEES

FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)

---

As the effects and impact of the global pandemic waned, it was agreed that the 2022 Annual Teaching Course, planned for September 2022 in Boston, USA, should be conducted in-person and preparations thus continued accordingly. This was the first annual course to be conducted in the USA and it represented an opportunity to spread awareness of the Society in north America where engagement with the Society had been at a lower level than Europe. It proved however to be a very challenging environment, both in terms of the cost of engaging services and the interest within that region to return to an in-person conference.

The meeting President, Professor Annick Van den Abbeele, secured substantial industry support and a significant number of companies participated, all providing excellent feedback to their experience of exhibiting despite the disappointing number of registered delegates. It is hoped that these companies will be keen to support future courses and longer term relationships can be established.

The ICIS pancreatic course planned for online delivery in November 2022 was postponed due to insufficient registrations and re-scheduled for March 2023. However, a new edition of the very successful ICIS masterclass on whole-body MRI was developed for classroom delivery in December 2022. Due to demand, the course was repeated on a second day, with excellent feedback received from all who participated.

A re-branded version of the 'Read with the Experts' series, first trialled in October 2021, was launched in February 2023. A series of six segments throughout 2023 will be conducted on hepatobiliary imaging, each curated by an ICIS Fellow. This series will be delivered through the CMRAD platform, with each segment, comprising five cases and associated MCQs. Registrants will have access to review the cases and submit answers to the MCQs. A webinar will be conducted subsequently, hosted by the respective Fellow, at which the diagnosis and correct answer to each case will be revealed. Registration is free to ICIS members; £20 per segment for non-members. This has been marketed as a quiz; at the end of the series, a prize will be awarded for the registrant who has achieved the highest score overall across all six segments. It is hoped that this novel format for learning will encourage increased engagement within the worldwide radiology community and be a source of new Society members as the cost of participating in the overall series is reduced by signing up for membership.

The opportunity to attend the Radiological Society of North America 2022 Annual Scientific Meeting (RSNA) with a complimentary Society booth, was again granted by the Board of RSNA following review of the Society's educational mission. RSNA is the world's largest radiological conference and this presented an opportunity to promote the Society, the Society journal 'Cancer Imaging' and the forthcoming annual teaching course ICIS 2023 to be held in London.

ICIS satellite meetings have remained on hold during the period under review; however, an invitation has been received to participate in the Korean Congress of Radiology (KCR), in Seoul, in September 2023. In addition, discussions have taken place with Taiwanese colleagues to participate in the 22nd Asian Oceanian Congress of Radiology (AOOR 2024) in Taiwan in March 2024. The Satellite Committee, now under the Chairmanship of Dr. Beth McCarville, is reviewing possible partnerships with international contacts to restart a programme of collaborations as the satellite activities are considered an important part of the Society's educational output to reach and teach colleagues around the globe.

Opportunities for improving international visibility of the Society are under constant review and ways to market our events worldwide. Social media tools are utilised to disseminate information, alongside mailings, advertising and the monthly e-newsletter. Regular social media activity is maintained through a range of platforms (Twitter, LinkedIn, Facebook, and YouTube) and the ICIS website is regularly updated to provide current and accurate information. Promoting the Society aims to increase membership, attendance at teaching courses and readership of 'Cancer Imaging' with a view to strengthening the Society's profile, its outreach and influence, as well as generating income for the Society. All these channels enable dissemination of knowledge in oncological imaging and promote education and research in this specialist field.



## INTERNATIONAL CANCER IMAGING SOCIETY

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)

---

'*Cancer Imaging*' continues to be published by BioMed Central as an online open access journal. Following the decline in submissions experienced in the post-pandemic period, levels returned and exceeded any previous record. Whilst this impacted substantially on the work required by the editors-in-chief and requested of the editorial board, the overall performance of the journal surpassed its own history by achieving an Impact Factor (IF) of 5.605 in June 2023, the highest ever recorded. This ranked 'Cancer Imaging' within the first quartile in Radiology journals at 27/136 and second quartile in Oncology journals at 79/245, producing a 5-year IF of 4.980. Close collaboration between the publishers, Editors-in-Chief and the editorial team has stimulated this success and contributed to the journal's further growth and development. The number of articles accessed continued to increase throughout the year demonstrating the ongoing interest in the journal.

Professor Rodney Hicks of St Vincent's Hospital, Melbourne, Australia, and Professor Annick Van den Abbeele from the Dana Farber Cancer Institute, Boston, USA, are Joint Honorary Editors-in-Chief, with Professor Stefan Diederich from the Marien Hospital Düsseldorf, Germany, as Deputy Editor. The Editorial Board works to develop the pool of submission reviewers able to take on this important work in a timely manner, whilst supporting the Editors-in-Chief with plans to develop 'Cancer Imaging' further.

Society membership levels are monitored regularly and remain lower since the onset of the pandemic. Numbers are generally boosted through registration to the annual teaching course and the knock-on effect of cancelling the 2020 annual course, the purely online delivery of the 2021 course, and lower registrations achieved for the 2022 annual course has reduced the number of people choosing to renew or take up membership of the Society.

At 28 February 2023, the number of Society members was 142 representing 35 countries worldwide; the number of Fellows was 86 and one Associate Fellow, representing 21 countries.

#### **Structure, Governance and Management**

The International Cancer Imaging Society is a company limited by guarantee, incorporated in England & Wales, and a registered charity, governed by its memorandum and articles of association.

The Society is governed by a Board of trustees that oversees the management of the activities which the charity runs. The charity trustees are also Directors of the Company limited by guarantee. Trustees are appointed by a vote of existing Trustees on the recommendation of a single Trustee. All Trustees with the exception of the treasurer have to be a Fellow of the Society.

The number of Trustees shall not be less than seven but shall not be subject to any maximum. Trustees remain in office for an initial term of six years. Trustees who indicate their willingness to do so, may continue in office for a subsequent term if this is agreed with other Trustees and Fellows.

Fellowship of the Society is restricted to physicians who have made a significant contribution to oncological imaging and are involved or interested in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any existing Fellow of the Society may apply to the Trustees to be considered for the status of Emeritus Fellow.



## INTERNATIONAL CANCER IMAGING SOCIETY

### REPORT OF THE TRUSTEES

FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)

---

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Membership of the Society is open to healthcare professionals with an interest in cancer imaging and in promoting the goals of the Society but who do not meet the criteria for Fellowship or do not wish to become a Fellow. Benefits of membership include reduced registration fees for Society teaching courses, access to the members' area of the website with its expanding repository of recorded lectures and scientific posters and a 20% discount on the article processing charge for accepted publications in Cancer Imaging.

During the period under review the Trustees convened on two occasions, in March 2022 online by virtual means due to the ongoing pandemic, and in a hybrid format in September 2022, on the day before the commencement of the annual teaching course.

Day to decision and activities of the Society are delegated by the trustees to the Executive Board

The Chair of the Executive Board reported to both Trustees' meetings, outlining the Board's ongoing work, including monitoring all Society activity and the work of the ICIS Secretariat. Meetings of the Executive Board were held in April, July and November 2022, and January 2023. These meetings were all conducted virtually enabling online participation of the internationally based Board members.

The Executive Board considers it judicious to maintain review of Society policies to ensure robust governance. The risk register is reviewed before each meeting to highlight any potential issues which could have a detrimental impact on the Society, identifying measures to mitigate and manage any risk.

The activity implemented by the three sub-committees set up to oversee the ICIS Interactive programme, e-learning, and social media and communications is reviewed at each Executive Board meeting, ensuring a focus on opportunities to develop key elements of Society activity. Consideration is also given to the benefits of Society membership with the intention of retaining existing and attracting new members.

Compliance with the General Data Protection Regulations (GDPR) is maintained in line with the UK General Data Protection Regulation (UK GDPR 2018), tailored by the Data Protection Act 2018, and subject to monitoring by the Society registration with the Information Commissioner's Office.

### Risks

The introduction of the risk register has enabled regular review by the Executive Board of any potential risk the Society may face, with any such risks reported to the Trustees. Establishing ways to generate additional income streams and promoting the Society worldwide remain a top priority. Proposed developments will be reviewed to ensure that the perceived benefits would outweigh the possible risk to the Society, which needs to maintain a viable, modern, robust structure from which to operate and develop bearing in mind any financial implications or impact on Society reserves.



## **INTERNATIONAL CANCER IMAGING SOCIETY**

### **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)**

---

The continued global interest in online educational activity in a very competitive virtual environment poses a new challenge and risk to the Society. Having migrated a portion of activity to online delivery, it is important to maintain the Society's reputation as a provider of high-quality education on oncological imaging, with articles published in 'Cancer Imaging' supporting retention of the journal's international standing amongst other journals providing sound research articles and reviews. Enhancing the value of ICIS membership will mitigate the risk of lower member numbers, whose support is an integral element of the Society's continued growth and success.

The Trustees have considered other possible risks the Society may be open to, and although the education is based within the very specialist field of oncology, the Trustees believe the study, analysis and promotion of research in this area does not open the Society itself to the risk of litigation from any third party. Commercial risks of operation include the running of the annual teaching course and the ICIS Interactive workshop series.

The financial implications to the Society of any future satellite meetings will be carefully analysed to ensure that the Society is not exposed to additional financial risks, and the progress of 'Cancer Imaging' will be kept under regular review.

The Trustees also take into consideration potential disasters such as floods, fires, earthquakes, volcanoes, international instability and terrorism that could affect plans for Society teaching courses, particularly those planned as in-person events. The risk posed by infectious diseases remains under review in the light of any potential international instabilities posed by variants of the COVID-19 pandemic. Close monitoring will be maintained to ensure any perceived risk to the Society is assessed in detail and precautions taken as necessary. The Executive Board will continue to keep all these risks under review and report to the Trustees. The city and venue for the Annual Teaching Course is chosen carefully and where possible, a break clause is included in the venue contract to mitigate potential risks. Insurance is reviewed every year.

#### **Reference and administrative details**

The Secretariat comprises two part-time employees, supported by contractors, who together maintain full and proper administrative control of all Society activities.

Engagement of personnel continues with two-yearly renewable contracts to allow for appropriate review, including salaries. ICIS does not have a central office facility for personnel, thus overhead running costs are reduced; the administrative team work individually remotely but maintain frequent virtual contact to provide efficient and timely attention to all matters.

During the period under review, significant additional pressure was placed on the Secretariat team by the sudden unexpected loss of the web manager, a key member of the administrative team. A web management company, Blue Flamingo Solutions, has been contracted to undertake management of the website and Society administrative system, covering a proportion of the duties previously undertaken by the Society web manager. Recruitment of an additional part-time member to the Secretariat team is underway to ease the burden of the additional workload placed on the existing personnel.

The Secretariat remain committed to enhancing engagement within the international radiology community to raise the profile of the Society and encourage registration for teaching courses, to deliver successful courses and secure income for the Society.



## INTERNATIONAL CANCER IMAGING SOCIETY

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)

---

#### Financial Review

The Trustees and the Executive Board continue to monitor Society finances and financial reserves closely, with monthly review of management accounts undertaken by key personnel. In the post-pandemic world, a shift of delegate preference has emerged which appears to have reduced the appetite for attending in-person conferences and a desire for online education. This shift may pose additional challenge when planning future teaching courses and securing commercial sponsorship for the Society overall and individual teaching courses, taking into account potential lower numbers of registrants.

The Society's corporate sponsorship package aims to secure notable financial commitment to the Society by industry leaders. These sponsorship agreements facilitate robust financial planning and forecasting, are re-negotiated for each contract term, although a level of adverse impact has been demonstrated since the pandemic and ongoing worldwide economic pressures.

Siemens Healthineers, a machine manufacturing company, have continued their support but at the slightly reduced level for this current period. Guerbet, a contrast media company, are renewing their agreement, potentially at an increased level for the forthcoming period.

The option of delivering ICIS Interactive Masterclass series online remains a valued source of income as preference is expressed by delegates for this format.

Substantial industry support was secured by the ICIS 2022 President which helped to defray the unexpectedly high costs associated with the ICIS 2022 meeting, and reduce the financial impact of lower delegate registrations. Following the 2022 annual teaching course, the recorded content was made available for purchase as a package of online content, with access available online until 1 September 2023. This is a new model and to date has generated a modest level of income which will offset some of the costs of providing content in this format. This will be reviewed for future course content.

'Cancer Imaging' remains a significant element of the Society's overall success. Royalty payments based on revenue from published articles and an incentive bonus payment dependent on achievement of pre-determined targets have both provided a beneficial income stream for the Society.

The publishers conduct an annual review of the Article Processing Charges (APC) and whilst the option to apply a surcharge to the APC remains, the proceeds of which would provide direct additional income for the Society from each article published, it is important to remain mindful of the potential impact this could have to limit the journal's attractiveness to authors or reduce the number of submissions.

Global economic challenges, in the wake of the extended pandemic, apparent hesitation to register for in-person courses, accompanied by reluctance to commit to travel, the increased costs associated with travel and hotels, have all contributed to a challenging financial period for the Society. The Trustees therefore have to report a deficit in Society reserves to the year ending 28 February 2023, despite the stringent approach to control of Society expenditure.

The Trustees will remain vigilant in overseeing Society activity and proposals for future income generation to assure a long-term future for the Society, and remain optimistic that a return to pre-pandemic behavior towards conference attendance and travel will emerge as confidence is restored.



## INTERNATIONAL CANCER IMAGING SOCIETY

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)

---

#### Reserves Policy

The Society's policy is to strive to build and hold reserves sufficient to confidently plan to run at least two future annual teaching courses, our flagship event and significant income stream, and be able to provide cover for one failed teaching course. The Society had reserves of £319,414 that were not invested in fixed assets at the year end to February 2023; (2022: £357,740).

#### Plans for the future

On behalf of the Trustees, the Executive Board and sub-committees work to improve and expand the educational portfolio of the Society, reaching additional colleagues in the radiology community internationally and ensuring a stable financial future to permit further growth and development. The annual teaching course and the ICIS Interactive Masterclass workshop series are two key components to this strategy, in addition to attracting high levels of sponsorship, to generate sufficient income to offset the costs of the administrative structure and add to reserves. The pandemic has necessitated additional focus on careful review of future Society activity.

Whilst there has been some global shift to virtual meetings, online fatigue has encouraged a return to in-person meetings, with the associated networking opportunities. The Executive Board has considered the balance of virtual against in-person meetings and decided that in-person meetings will be reinstated as an integral part of Society activities in 2023.

The third ICIS in Focus meeting covering Artificial Intelligence and Machine Learning in Cancer Imaging will be held in Lisbon in June 2023, supported by the Champalimaud Foundation. The level of financial support previously provided in 2019 will not be available due to the impact of the pandemic on Foundation reserves; however, industry sponsorship is being sought to offset costs of the meeting and to generate a surplus.

The 2023 annual teaching course will be delivered in-person at the British Museum in London, 25-27 September 2023, re-arranged following cancellation of the 2020 annual teaching course and utilising the deposit initially paid for that reservation. It is hoped that returning to same venue in London as the extremely successful 2015 annual course will prove to be financially beneficial. The theme of the meeting will be 'Cancer Imaging: Current guidelines for best practice' with the aim of providing valuable updates for the international radiological and nuclear medicine communities over the course of the three-day meeting, alongside the latest research and developments in the specialist field of cancer imaging.

In view of the costs associated with provision of hybrid delivery, ICIS 2023 will be planned purely as an in-person meeting with the intention of attracting national and international colleagues to re-engage in the iconic setting of the British Museum. The meeting President has secured industry support for the meeting in addition to Society corporate sponsorship; together with registration fee income, this financial support is expected to provide a sound basis from which to deliver a successful event with positive financial outcome.

The President for the annual teaching course in 2024 is based in Singapore. Whilst previous satellite activities have introduced the Society to the Asian market, and recent invitations to participate in the KCR 2024 and AOCR 2024 conferences offer this opportunity, an annual teaching course has never been held in this geographical region. The Singapore Radiological Society (SRS) traditionally conduct their annual course in August, and to avoid direct competition, a collaboration to conduct a joint meeting with the SRS is being explored. This will enable a larger more diverse programme and mitigate some of the anticipated risk of a new, previously untested market for ICIS. In advance of the 2024 annual teaching course, it is hoped to deliver at least one online ICIS Interactive Masterclass to promote the Society and generate interest in the annual course.



## INTERNATIONAL CANCER IMAGING SOCIETY

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)

---

Two new ICIS Interactive Masterclass workshops have been developed to expand the portfolio of topics. The workshop on head and neck tumours previously planned for launch in February has been postponed to April 2023. In addition, a new workshop on renal/adrenal tumours is planned for May 2023. Initial delivery is planned as a classroom course, with a view to migrating online in the future.

Further plans to revise the ICIS Interactive thoracic course are on hold pending publication of updated staging guidelines with a view to including the latest information in the updated content.

A new opportunity is being pursued whereby the ICIS Interactive Masterclass in whole-body MRI will be delivered in a hybrid format. This is being conducted in collaboration with the South African Congress of Oncology, to be held in September 2023; one ICIS faculty member will be onsite in Cape Town and the other ICIS faculty will join to teach via Zoom. Delegates will have their own workstation for individual case review throughout the course, with the usual workbook provided. Cases will be hosted on the CMRAD platform and access will be enabled for participants during the course. If this model is successful, the learning experience is considered acceptable and positive feedback is received, it is likely to be considered for future occasions and will open the opportunity to engage with other international societies to offer this delivery format for any masterclass in the portfolio.

The new relationship with Collective Minds Radiology has translated into an annual contract which provides the opportunity for delivery of a number of ICIS Interactive Masterclasses throughout the year at an established fee and without the risk of increased charges, as had been the case with the London venue previously used. This should facilitate a more accurate projection of the financial outcome of the ICIS Interactive series and keep preparation costs at a reduced level.

Following the loss of the web manager, it has become apparent that the technology behind the Society website and administrative system is outdated. A review of the whole system is currently underway, with input from the newly appointed web management team, Blue Flamingo Solutions; it is anticipated that a new website and administrative system should be developed over the coming year.

Establishing an e-learning platform for the Society has been postponed as other activity has precluded the opportunity to develop appropriate content into self-directed e-learning modules on a suitable online platform. Material from retired first edition ICIS Interactive Masterclass courses may be adapted to create modules for independent learning. A charge would be levied for each module, thereby generating an additional income stream for the Society.

The opportunity to re-introduce in-person satellite meetings will be kept under review taking into account the international travel and ensuring those who represent the Society are not exposed to any unnecessary risk. These meetings do present an opportunity to enhance the international profile of the Society, and enable radiologists in locations otherwise unable to attend ICIS teaching courses to benefit from the knowledge and expertise of the ICIS Fellows; this however has to be balanced against the other logistical factors. The possibility of linking virtually with previous satellite partners may be explored, but potential online fatigue versus the value of in-person meetings will be factored into any decision.

A financial appraisal of any proposed satellite venue is reported to the Trustees to ensure no financial risk is posed to the Society. The Society does not cover any of the speaker expenses; these costs must be met by the host societies or personally.

## INTERNATIONAL CANCER IMAGING SOCIETY

### REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)

---

Marketing Society activities and 'Cancer Imaging' will remain a priority; electronic means and social media enable enhanced communication with members and the wider international community with an interest in oncological imaging. Developing further membership benefits will be reviewed to maintain and increase membership numbers, and assessment of options presented by online education to assist in promoting the Society and enhancing the appeal of membership. Google analytics of traffic to the ICIS website permits review of activity and the number of members will continue to be monitored regularly. Electronic surveys allow a quick and efficient method of communicating and provide engagement with membership and course delegates to seek valuable opinion.

By order of the Board on 24 September 2023



**Trevor Pereira**  
Secretary



**INDEPENDENT EXAMINER'S REPORT  
TO THE TRUSTEES OF  
INTERNATIONAL CANCER IMAGING SOCIETY**

---

I report to the charity trustees on my examination of the accounts of the Company for the year ended 28<sup>th</sup> February 2023 set out on pages 12 to 17.

**Responsibilities and basis of report**

As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102)

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



**Paul Newton FCA**  
**Jacob Cavenagh & Skeet**  
5 Robin Hood Lane  
Sutton  
Surrey  
SM1 2SW

Date: 2 October 2023

# INTERNATIONAL CANCER IMAGING SOCIETY

## STATEMENT OF FINANCIAL ACTIVITIES (incorporating the income and expenditure account) FOR THE YEAR ENDED 28TH FEBRUARY 2023

	<b>Note</b>	<b>Unrestricted 2023 £</b>	<b>Unrestricted 2022 £</b>
<b>Income from</b>			
<i>Charitable activities</i>			
Conference sponsorship and funding		202,957	102,489
Revenue from conference delegates		43,341	45,054
Membership income		21,299	17,317
ICIS Interactives		35,266	34,102
Journal income		16,575	13,423
Interest receivable		1,967	447
<b>Total income</b>		<b>321,405</b>	<b>212,832</b>
<b>Expenditure on</b>			
<i>Charitable activities</i>			
Conference costs		190,472	20,239
Design, production and advertising		7,421	3,233
Administration			
- Data Manager		4,120	9,557
- Events & Marketing, and General Manager	6	72,560	70,214
- Secretarial Services		8,972	-
- Other		2,500	2,500
Pension Scheme		335	310
Travel and accommodation		15,806	4,793
Printing		6,377	6,919
Bank charges and credit card charges		2,601	2,106
Gifts and donations		100	174
Insurance		1,773	1,111
Accreditations		435	761
Utilities		226	-
Postage/delivery charges		529	1,251
Telephone		577	115
Depreciation		202	270
Software expenses		1,805	1,863
IT support		12,033	-
Miscellaneous		835	561
Rent		977	2,114
Licenses and Permits		553	95
Subscriptions		13	13
Accounting		38,918	34,436
Professional Fees		2,124	-
Consultancy Fee		300	-
Governance cost: Independent Examiners fees		2,079	2,079
Foreign exchange losses/(gains)		( 14,104)	9,116
<b>Total expenditure</b>		<b>360,539</b>	<b>173,830</b>
<b>Net (expenditure)/income and movement in funds</b>		<b>( 39,134)</b>	<b>39,002</b>
<b>Reconciliation of funds</b>			
Unrestricted fund balance brought forward		358,548	319,546
<b>Unrestricted fund balance carried forward</b>		<b>319,414</b>	<b>358,548</b>

The notes on pages 14 to 17 form part of these financial statements.



# INTERNATIONAL CANCER IMAGING SOCIETY

## BALANCE SHEET AS AT 28TH FEBRUARY 2023


	Note	2023 £	2022 £
<b>Fixed assets</b>			
Tangible fixed assets	2	606	808
<b>Current assets</b>			
Debtors	3	37,506	162,748
Cash at bank and in hand		<u>308,446</u>	<u>358,396</u>
		345,952	521,144
<b>Creditors: Amounts falling due within one year</b>	4	<u>27,144</u>	<u>163,404</u>
<b>Net current assets</b>		<u>318,808</u>	<u>357,740</u>
<b>Total Net assets less current liabilities</b>		<u>319,414</u>	<u>358,548</u>
<b>Unrestricted Funds</b>	5	<u>319,414</u>	<u>358,548</u>

These accounts have been prepared in accordance with the provisions available to companies subject to the small companies' regime within Part 15 of the Companies Act 2006.

For the financial year ended 28 February 2023 the company was entitled to exemption from audit under section 477 Companies Act 2006. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company.

The financial statements were approved by the Board on 24 September 2023 and signed on their behalf by:



**Prof. Anwar Padhani**  
Trustee



**Prof. Dow Mu Koh**  
Trustee

**Company Registration number: 03908709**

The notes on pages 14 to 17 form part of these financial statements.

# INTERNATIONAL CANCER IMAGING SOCIETY

## NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2023

---

### 1 ACCOUNTING POLICIES

**(a) Basis of accounting**

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006, applicable accounting standards and with the Statement of Recommended Practice (Charities SORP (FRS 102)) and Financial Reporting Standard 102 (FRS 102). The financial statements are prepared in pounds sterling rounded to the nearest pound.

International Cancer Imaging Society meets the definition of a public benefit entity under FRS 102. The Society is a company limited by guarantee registered in England & Wales with its registered office at 41 Waddington Way, London, SE19 3UB.

**(b) Going concern**

There are no significant uncertainties about the charity's ability to continue as a going concern.

**(c) Income recognition**

Donations and other income are included in the Statement of Financial Activities (SOFA) when the charity has entitlement to the income, it is probable the income will be received and the amount of income receivable can be reliably measured.

Revenue grants are accounted for on an accruals basis, matching it to the actual projects undertaken in the period rather than uniformly over the grant period.

Income received from delegates and sponsors for courses are recorded in the year the course takes place.

**(d) Expenditure recognition**

All expenditure is accrued as soon as a liability is considered probable, discounted to present value for longer term liabilities and has been classified under headings that aggregate all costs related to the category

Charitable activities comprise expenditure directly related to the objects of the charity, including administration and support functions including any related provisions. It also includes governance costs, which comprise expenditure to comply with statutory and legal requirements

**(e) Irrecoverable VAT**

Irrecoverable VAT is included with the expense upon which it is incurred.

**(f) Transactions in foreign currencies**

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction. Assets and liabilities at the balance sheet date are translated into sterling at the rate ruling at the balance sheet date. All resultant differences arising from the above policy are dealt with in the Statement of Financial Activities.

**(g) Tangible fixed assets**

Tangible fixed assets are depreciated at the following annual rates:

Computer equipment – 25% (reducing balance basis)



# INTERNATIONAL CANCER IMAGING SOCIETY

## NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)

### 1 ACCOUNTING POLICIES (CONTINUED)

**(h) Cash at bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of opening of the deposit.

**(i) Creditors and provisions**

Creditors and provisions are recognised where the charity has a present obligation arising from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are recognised at their settlement amount

**(j) Financial instruments**

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

### 2 TANGIBLE FIXED ASSETS

	<b>Computer equipment</b>	<b>Total</b>
	<b>£</b>	<b>£</b>
<b>Cost</b>		
As at 1st March 2022	1,150	1,150
Additions	-	-
Disposals	-	-
As at 28th February 2023	<u>1,150</u>	<u>1,150</u>
<b>Depreciation</b>		
As at 1st March 2022	342	342
Charge for year	202	202
Disposals	-	-
As at 28th February 2023	<u>544</u>	<u>544</u>
<b>Net book value</b>		
As at 28th February 2023	<u>606</u>	<u>606</u>
As at 29th February 2022	<u>808</u>	<u>808</u>

### 3 DEBTORS

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Trade debtors	22,820	149,658
Prepayments and accrued income	<u>14,686</u>	<u>13,090</u>
	<u>37,506</u>	<u>162,748</u>

# INTERNATIONAL CANCER IMAGING SOCIETY

## NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)

### 4 CREDITORS

	2023 £	2022 £
Trade creditors	1,899	765
Accruals and deferred income	<u>25,245</u>	<u>162,639</u>
	<u>27,144</u>	<u>163,404</u>

### 5 MOVEMENT ON FUNDS

	At 1 <sup>st</sup> March 2022 £	Total Income £	Total Expenditure £	At 28 <sup>th</sup> February 2023 £
<b>Unrestricted Funds</b>				
General Fund	<u>358,548</u>	<u>321,405</u>	<u>(360,539)</u>	<u>319,414</u>

	At 1 <sup>st</sup> March 2021 £	Total Income £	Total Expenditure £	At 29 <sup>th</sup> February 2022 £
<b>Unrestricted Funds</b>				
General Fund	<u>319,546</u>	<u>212,832</u>	<u>(173,830)</u>	<u>358,548</u>

### 6 STAFF COSTS

	2023 £	2022 £
Salaries	68,585	65,949
Pension	1,667	1,604
Social security	<u>2,308</u>	<u>2,661</u>
	<u>72,560</u>	<u>70,214</u>
Average no. staff	<u>2</u>	<u>2</u>

No employee earned over £60,000 in the year, nor in the previous financial year.

The total employee benefits of the key management personnel of the charity as listed on page 1 were £49,505 (2022: £46,014). There were no other related party transactions in the year.



# **INTERNATIONAL CANCER IMAGING SOCIETY**

## **NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 28TH FEBRUARY 2023 (continued)**

---

### **7 TRUSTEES' REMUNERATION**

None of the trustees received any remuneration from the charity during the year (2022: none). Expenses incurred on behalf of the Society and reimbursed to trustees during the year to 28th February 2023 amounted to £nil (2022: £nil).

In accordance with the Articles of Association, the Trustees may be paid all reasonable travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Trustees or committees of Trustees or general meetings or otherwise in connection with the discharge of their duties, but shall otherwise be paid no remuneration.

### **8 LIMITED BY GUARANTEE**

The company is limited by guarantee, each member (termed "Fellow" from October 2004) having guaranteed to pay £1 should the company be wound up.